Chemical Engineering, School for the Engineering of Matter, Transport, and Energy, Arizona State University, Tempe, AZ, USA.
Department of Pathology, School of Medicine, Case Western Reserve University, Ohio, OH, USA.
Nat Commun. 2024 Nov 11;15(1):9739. doi: 10.1038/s41467-024-54227-9.
Biomaterials can act as pro- or anti-inflammatory agents. However, effects of biomaterials crystallinity on immune responses are poorly understood. We demonstrate that the adjuvant-like behaviour of covalent organic framework (COF) biomaterial is dependent on its crystallinity. COF crystallinity is inversely correlated with the activation of mouse and human dendritic cells (DC), but with antigen presentation by mouse DCs only. Amorphous COFs upregulates NFkB, TNF, and RIG-I signalling pathways, as well as the chemotaxis-associated gene Unc5c, when compared to crystalline COFs. Meanwhile, Unc5c inhibition disrupts the correlation between crystallinity and DC activation. Furthermore, COFs with the lowest crystallinity admixed with chicken ovalbumin (OVA) antigen prevent OVA-expressing B16F10 tumour growth in 60% of mice, with this protection associated with the induction of antigen-specific, pro-inflammatory T cell. The lowest crystalline COFs admixed with TRP2 antigen can also prevent non-immunogenic YUMM1.1 tumour growth in 50% of mice. These findings demonstrate that the crystallinity of biomaterials is an important aspect to consider when designing immunotherapy for pro- or anti-inflammatory applications.
生物材料可以作为促炎或抗炎剂。然而,生物材料结晶度对免疫反应的影响还知之甚少。我们证明了共价有机骨架(COF)生物材料的佐剂样行为取决于其结晶度。COF 的结晶度与小鼠和人树突状细胞(DC)的激活呈负相关,但仅与小鼠 DC 的抗原呈递有关。与结晶 COF 相比,无定形 COF 上调 NFkB、TNF 和 RIG-I 信号通路以及趋化相关基因 Unc5c。同时,Unc5c 抑制破坏了结晶度与 DC 激活之间的相关性。此外,与鸡卵清蛋白(OVA)抗原混合的结晶度最低的 COF 可预防表达 OVA 的 B16F10 肿瘤在 60%的小鼠中生长,这种保护与诱导抗原特异性、促炎 T 细胞有关。与 TRP2 抗原混合的结晶度最低的 COF 也可以预防无免疫原性 YUMM1.1 肿瘤在 50%的小鼠中生长。这些发现表明,在设计用于促炎或抗炎应用的免疫疗法时,生物材料的结晶度是一个需要考虑的重要方面。
Nat Commun. 2024-11-11
Oncotarget. 2016-7-12
Cancer Immunol Immunother. 2008-11
J Biomed Mater Res A. 2025-7
Nat Rev Bioeng. 2023-2
Nat Rev Chem. 2022-12
Front Immunol. 2022
ACS Appl Mater Interfaces. 2022-7-13